科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background: Several studies have explored the relationship between methionine synthase reductase (MTRR) A66G polymorphism and non-Hodgkin lymphoma (NHL) risk, however, the published results were controversial. Thus, a meta-analysis was performed to provide a more precise estimate of the association of MTRR A66G polymorphism with NHL risk. Methods: The PubMed, Elsevier, China National Knowledge Infrastructure and Wanfang Databases were searched (up to February 01, 2015) to collect case-control studies investigating the relationship between MTRR A66G polymorphism and NHL risk. Odds ratios (ORs) with 95% confidence intervals (CIs) were applied to assess the strength of association. Results: Finally, five case-control studies, bearing 1357 cases and 3374 controls, were included in this meta-analysis. The results of overall comparisons suggested that there was no significant association between MTRR A66G polymorphism and NHL risk under all four genetic models (AG vs. AA: OR=0.97, 95% CI=0.84-1.11, P=0.65; GG vs. AA: OR=1.06, 95% CI=0.85-1.31, P=0.62; GG vs. AA+AG: OR=1.02, 95% CI=0.85-1.23, P=0.84; AG+GG vs. AA: OR=0.99, 95% CI=0.87-1.13, P=0.90). In the subgroup analyses by ethnicity and NHL subtype, significant association was found in Asians (GG vs. AA: OR=1.32, 95% CI=1.011.72, P=0.04; GG vs. AA+AG: OR=1.34, 95% CI=1.03-1.73, P=0.03) and diffuse large B-cell lymphoma (DLBCL) in overall population (GG vs. AA: OR=1.46, 95% CI=1.05-2.03, P=0.02; GG vs. AA+AG: OR=1.46, 95% CI=1.06-2.00, P=0.02). Conclusion: The present meta-analysis suggested that MTRR A66G polymorphism was associated with an increased risk for NHL in Asian populations and for DLBCL in whole population. Further well-designed studies based on larger sample sizes are required to confirm these findings.
- 出版日期2016
- 单位河南大学
